TLDR:
- Discure Technologies secures $16 million in financing led by BOLD Capital Partners, Supernova Invest, and Sanara Capital.
- Funds will advance the clinical testing of Discure’s device for degenerative disc disease.
Discure Technologies, a developer of a bioelectronic implantable device for the treatment of degenerative disc disease (DDD), has announced securing $16 million in financing. The Series A round was led by BOLD Capital Partners, Supernova Invest, and Sanara Capital, with participation from multiple US hospital networks, orthopedic surgeons, and medtech industry investors. This investment will accelerate the company’s growth, allowing for key hires and funding of their First-in-Human clinical study in Canada and Italy.
Discure’s innovative approach to addressing the underlying cause of DDD has garnered interest from investors like BOLD Capital Partners and Supernova Invest. The company’s focus on reversing disc degeneration by reintroducing fluid, oxygen, and nutrients into the degenerated disc sets it apart from existing treatments that only offer symptom relief with limited long-term benefits. The Discure System received Breakthrough Device Designation from the FDA in 2021 and is currently undergoing a First-in-Human clinical trial.
Low back pain, a leading cause of disability globally, is often linked to DDD. Current treatments for DDD involve opioids, injections, and invasive surgery, providing only temporary relief. Discure’s unique solution aims to offer a disease-modifying alternative that reduces the need for opioids and invasive procedures.
Investors in Discure Technologies include Bold Capital Partners, Supernova Invest, Sanara Capital, JJDC, UVM Health Network Ventures, and VTC Ventures. The company’s focus on disruptive technology in the healthcare industry has attracted attention from investors looking to support innovative solutions to common health issues.
